We confirmed that HUWE1 silencing leads to PARPi resistance using either talazoparib or olaparib in parental SUM149 cells (without sg-GFP, Fig. 2A, B) and in another tumour cell line with a pathogenic exon 11 frameshift BRCA1 mutation, UWB1.289 (high grade serous ovarian cancer, referred to as UWB1, Fig. 2C, D). This evidence concerns the gene BRCA1 and ovarian serous adenocarcinoma.